Peer-reviewedCC BY 4.0Journal of Human Immunity
Severe dengue: Are type I interferon autoantibodies involved?
13 affiliations
- 1Laboratory of Human Genetics of Infectious Diseases, University of Texas Southwestern, Dallas, TX, USA
- 2Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center, Dallas, TX, USA
- 3Neonatal and Pediatric Intensive Care Unit, Mother, Child and Adolescent Department, Geneva University Hospitals, Geneva, Switzerland
- 4Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland
- 5Host-Pathogen Interaction Unit, San Matteo Research Hospital (Fondazione IRCCS Policlinico San Matteo), Pavia, Italy
- 6Global Health Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- 7Laboratory of Human Genetics of Infectious Diseases, Université Paris Cité, Institut Imagine, Necker Branch, INSERM UMR 1163, Paris, France
- 8Department of Pediatrics, University of Texas Southwestern, Dallas, TX, USA
- 9Department of Immunology, University of Texas Southwestern, Dallas, TX, USA
- 10Children’s Hospital Research Institute, Dallas, TX, USA
- 11Howard Hughes Medical Institute, New York, NY, USA
- 12Department of Neurology, University of Texas Southwestern, Dallas, TX, USA
- 13Department of Neuroscience, University of Texas Southwestern, Dallas, TX, USA
Abstract
Dengue virus (DENV) is the most rapidly disseminating arbovirus worldwide. A new study by Yang et al. (https://doi.org/10.70962/jhi.20260072) shows that autoantibodies neutralizing type I IFNs (AAN-I-IFN) may underlie severe dengue in ∼14% (7/49) of cases in a cohort of Chinese patients. Further studies of children and adults of different ancestries with silent, benign, and severe DENV infection are warranted.
Related
- Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19.
- T-cell-mediated immunodeficiency caused by anti-interferon-γ autoantibodies promotes the pathogenesis of Talaromycosis marneffei
- Autoantibodies Against Type I Interferons and Death from H7N7 Avian Flu
- Narrative Review of the Bacterial Profile Involved in Severe COPD Exacerbations Complicated by Pneumonia in Patients Admitted to the Intensive Care Unit.
- Factor VIII inhibitors demonstrate type I or type II kinetics in high‐titre alloantibodies and autoantibodies
BibTeX
@article{tran2026severe,
title = {{Severe dengue: Are type I interferon autoantibodies involved?}},
author = {Vu Le-Huy Tran and Alessandro Borghesi and Jean-Laurent Casanova and Shen-Ying Zhang},
journal = {Journal of Human Immunity},
year = {2026},
month = nov,
doi = {10.70962/jhi.20260214},
url = {https://doi.org/10.70962/jhi.20260214},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Severe dengue: Are type I interferon autoantibodies involved?
AU - Vu Le-Huy Tran
AU - Alessandro Borghesi
AU - Jean-Laurent Casanova
AU - Shen-Ying Zhang
PY - 2026
DA - 2026/11/12
JO - Journal of Human Immunity
DO - 10.70962/jhi.20260214
UR - https://doi.org/10.70962/jhi.20260214
AB - Dengue virus (DENV) is the most rapidly disseminating arbovirus worldwide. A new study by Yang et al. (https://doi.org/10.70962/jhi.20260072) shows that autoantibodies neutralizing type I IFNs (AAN-I-IFN) may underlie severe dengue in ∼14% (7/49) of cases in a cohort of Chinese patients. Further studies of children and adults of different ancestries with silent, benign, and severe DENV infection are warranted.
SN - 3065-8993
ER -